Truth short folly

Somebody, using the name “Jen Lehman” has recently unlawfully pretended to represent “Study in Poland” recruiting students to Polish universities. Beware the person HAS NO RIGHT to use or refer to website survie-fr.info

Browse from more than 400 English study programmes in Poland!

Excellence put unaffected

 

Nay particular delightful

Academic schools

Vocational schools

Study in Poland - programme - survie-fr.info

University of Economics in Katowice

Joint Master’s Degree in European Business and Finance

degree

Master’s degree awarded by three universities

duration

2 years (4 semesters)

language

English

ECTS points

120

description

The overall aim is to develop managers originating predominantly from Central and Eastern Europe, capable of working in a pan-European cross-cultural business environment. The programme reflects a thorough analysis of the changing requirements for joint international business management programmes from student and international employer perspective. During the first two semesters students follow the courses at the Faculty of Finance and Insurance in Katowice. The final part of the programme comprises one semester in Nottingham Trent University and a one-semester-long work placement.

tuition

Information available at www.ue.katowice.pl/en/admission/fees.html

deadline

for EU students: 10 September/for non EU students: 10 July

contact

Faculty of Finance and Insurance
University of Economics in Katowice
1 Maja 50, 40-287 Katowice
Tel.: +48 32 257 7747
Fax: +48 32 257 7731
E-mail: [email protected]
Karolina Borys

www

www.ue.katowice.pl/en/admission/masters-degree-programmes/european-business-and-finance.html

institution

University of Economics in Katowice

education requirements

Bachelor or Master degree; each candidate should prove a good command of English. Detailed list of admission requirements available on www.ue.katowice.pl

There are three major facts that should be watched out for in all in the United States. On the global pharmaceutical market this medicine was issued in 2003 by two companies - Eli Lilly and ICOS. Initially, permission to sell was obtained in Europe, Australia, New Zealand.